Development and characterization of multilamellar liposomes containing pyridostigmine

Abstract Pyridostigmine has cardioprotective activity in both free and liposomal forms. This study aimed to develop and characterize liposomal formulations of pyridostigmine. For this, a spectrophotometric ultraviolet (UV) analytical method, at 270 nm, was developed and validated to quantify liposom...

Full description

Saved in:

Bibliographic Details
Published in:	Pharmaceutical development and technology Vol. 19; no. 4; pp. 454 - 459
Main Authors:	Souza, Ana Carolina Moreira, Grabe-Guimarães, Andrea, Souza, Jacqueline, Botacim, Wallace Entringer, Almeida, Tamara Marine, Frézard, Fréderic Jean Georges, Silva Barcellos, Neila Márcia
Format:	Journal Article
Language:	English
Published:	England Informa Healthcare USA, Inc 01-06-2014 Taylor & Francis
Subjects:	Chemistry, Pharmaceutical - methods Cholesterol - chemistry Drug Carriers - chemistry Liposomal matrix Liposomes - chemistry Particle Size Phosphatidylcholines - chemistry pyridostigmine Pyridostigmine Bromide - chemistry UV spectrophotometric method
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Pyridostigmine has cardioprotective activity in both free and liposomal forms. This study aimed to develop and characterize liposomal formulations of pyridostigmine. For this, a spectrophotometric ultraviolet (UV) analytical method, at 270 nm, was developed and validated to quantify liposomal pyridostigmine. The method was linear in ranges from 0.02 to 0.09 mg/mL. The accuracy of this method was determined intra- and inter-day; the results of coefficient of variation were of 1.73-2.72% and 0.32-2.32%, respectively. The accuracy ranged between 99.45% and 101.12%. The method has not changed by influence of liposomal matrix and demonstrated being able to quantify pyridostigmine in liposomes. Two liposomal multilamellar formulations were developed: a constituted by dystearoyl-phosphatidylcholine (DSPC) and cholesterol (CHOL) other by dioleil-phosphatidylcholine (DOPC) and CHOL. The encapsulation efficiency was determined as 23.4% and 15.4%, respectively. Analyses of size and release of pyridostigmine from the formulations were made and the results showed that the formulations are viable for future studies in vivo.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1083-7450 1097-9867
DOI:	10.3109/10837450.2013.795166